← Russell 3000 cross-section

FATE FATE THERAPEUTICS INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$306m
Revenue TTM
$6m
Net income TTM
$-126m
Free cash flow
$-106m
Composite score
30.4
Sector rank
#2644

Valuation

P / E
EV / EBITDA
EV / sales
23.4
FCF yield
-34.57%
Earnings yield vs 10-yr
-45.97pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-1,941.1%
EBITDA margin
-1,873.4%
ROE
-82.1%
ROIC
Revenue growth
-23.4%

Insider activity, last 90 days

Net open-market
$-0.20m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

As of December 31, 2025, aggregate deferred revenue related to the Ono Arrangement was $0.4 million. The decrease in revenue was primarily due to our achievement of a clinical development milestone during the year ended December 31, 2024, resulting in the recognition of $5.0 million in revenue during that period. The decrease in research and development expenses was attributable primarily to the following: • $9.5 million decrease in employee-stock based compensation expense; • $6.0 million decrease in depreciation expense; • $5.0 million decrease in third-party professional consultant expense; • $4.1 million decrease in laboratory materials and supplies expenses relating to the manufacture o …FATE THERAPEUTICS INC, 10-K, period ended 2025-12-31, filed 2026-02-26

Read the full passage →